Preview

Медицинский Совет

Расширенный поиск

Таргетный синтетический препарат для лечения псориатического артрита и псориаза – апремиласт

https://doi.org/10.21518/2079-701X-2018-12-136-141

Полный текст:

Аннотация

Апремиласт (АП), ингибитор фосфодиэстеразы-4, является новым препаратом для лечения псориаза (Пс) и псориатического артрита (ПсА). Лечение АП способствует уменьшению активности воспалительных изменений за счет снижения уровня провоспалительных цитокинов. Положительное влияние на Пс было доказано в клинических исследованиях, например, в  ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), в котором терапия АП привела к уменьшению индекса PASI у больных среднетяжелым и тяжелым бляшечным Пс: через 16 нед. 75%-ное улучшение PASI значительно чаще наблюдалось у больных, принимавших АП в дозе 30 мг 2 р/сут (33%), чем у больных при использовании плацебо (ПЛ) (5%) (p = 0,0001). В исследовании PALACE 1 на 16-й нед. лечения АП 20% улучшение по критериям ACR (ACR20) при использовании АП по 20 и 30 мг 2 р/сут отмечалось достоверно чаще, чем у больных, получавших ПЛ (в 30,4%, 38,1% и 19% случаев, р = 0,0166 и р = 0,0001 соответственно). После 52 нед. лечения АП ACR20 было достигнуто у 63,0% больных, принимавших препарат по 20 мг 2 р/сут, и 54,6% получавших 30 мг 2 р/сут. По данным РКИ (PALACE 1, 2, 3, 4), наиболее частыми неблагоприятными реакциями (НР) были диарея, тошнота, головная боль, инфекции верхних дыхательных путей и назофарингит. Большинство НР были легкой и средней степени тяжести, и частота отмены терапии из-за НР была низкой. На основании данных исследований PALACE, в которых участвовали 1493 больных, доказаны эффективность и  безопасность АП в лечении ПсА с умеренной активностью заболевания.

 

Об авторах

Ю. Л. Корсакова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

к.м.н.



Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

д.м.н.



Список литературы

1. Kane D, Staff ord L, Bresnihan B et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford), 2003, 42: 1460-1468.

2. Taylor WJ, Mease PJ, Adebajo A et al. Eff ect of psoriatic arthritis according to the aff ected categories of the international classifi cation of functioning, disability and health. J Rheumatol, 2010, 37: 1885-1891.

3. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun, 2010, 34: J314–21.

4. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum, 2009, 61: 1373–8.

5. Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford), 2013, 52: 568–75.

6. Zachariae H, Zachariae R, Blomqvist K et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol, 2002, 82: 108-113.

7. Rosen CF, Mussani F, Chandran V et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford), 2012, 51: 571-576.

8. Taylor W, Gladman D, Helliwell P et al. Classifi cation criteria for psoriatic arthritis, development of new criteria from a large international study. Arthritis Rheum, 2006, 54: 2665-2673.

9. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol, 2016, 68(5): 1060-1071. doi: 10.1002/art.39573.

10. Ash Z, Gaujoux-Viala C, Gossec L et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis, 2012, 71: 319-326.

11. Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis, 2012, 71: 4-12.

12. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol, 2009, 61: 451-485.

13. Shear NJ. Fulfi lling an unmet need in psoriasis: do biologics hold the key to improved tolerability? Drug Saf, 2006, 29: 49-66.

14. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today, 2005, 10: 1503-1519.

15. Tenor H, Hedbom E, Hauselmann HJ et al. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes-functional importance of phosphodiesterase 4. Br J Pharmacol, 2002, 135: 609-618.

16. Manning CD, Burman M, Christensen SB et al. Suppression of human infl ammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol, 1999, 128: 1393-1398.

17. Barber R, Baillie GS, Bergmann R et al. Diff erential expression of PDE4 cAMP phosphodiesterase isoforms in infl ammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol, 2004, 287: L332-343.

18. Bjorgo E, Tasken K. Role of cAMP phosphodiesterase 4 in regulation of T-cell function. Crit Rev Immunol, 2006, 26: 443-451.

19. Schafer PH, Parton A, Gandhi AK et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-infl ammatory activity in vitro and in a model of psoriasis. Br J Pharmacol, 2010, 159: 842-855.

20. Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, Hsueh RC et al. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal, 2009, 2: ra28. doi: 10.1126/scisignal.2000202.

21. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol, 2012, 83: 1583-1590.

22. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic infl ammatory diseases. Dermatol Ther (Heidelb), 2013, 3: 1-15.

23. Capone L, Rogovitz A, Gandhi AK et al. Anti-inflammatory activity of apremilast against T cells, chondrocytes, and rheumatoid arthritis synovial fibroblasts in vitro. Arthritis Rheum, 2011, 63(10 Suppl.): 1844.

24. Gottlieb AB, Strober B, Krueger JG. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-infl ammatory agent, apremilast. Curr Med Res Opin, 2008, 24: 1529-1538.

25. McCann FE, Palfreeman AC, Andrews M et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther, 2010, 12: R107.

26. Pathan E, Abraham S, Van Rossen E et al. Effi cacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis, 2013, 72: 1475-1480.

27. Genovese MC, Jarosova K, Cieślak D et al. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Arthritis Rheumatol, 2015 Jul, 67(7): 1703-1710. doi: 10.1002/art.39120.

28. Hatemi G, Melikoglu M, Tunc R et al. Apremilast for Behçet’s Syndrome – A Phase 2, Placebo-Controlled Study. N Engl J Med, 2015, 372: 1510-1518.

29. Papp K, Cather J, Rosoph L et al. Effi cacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet, 2012, 380: 738-746.

30. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatol, 2015, 73: 37-49.

31. Schett G, Wollenhautpt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: results

32. of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum, 2012, 64: 3156-3167.

33. Rich P, Gooderham M, Bachelez H et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with diffi cult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol, 2016 Jan, 74(1): 134-142. doi: 10.1016/j.jaad.2015.09.001.

34. Reich K, Gooderham M, Green L et al. The effi cacy

35. and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol, 2017 Mar, 31(3): 507-517.

36. Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Treatment of psoriatic arthritis in a phase 3, randomized controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis, 2014, 73: 1020-1026.

37. Edwards CJ, Blanco FJ, Crowley J et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. doi: 10.1136/annrheumdis-2015-207963.

38. Wells AF, Edwards CJ, Adebajo AO et al. Apremilast in the treatment of DMARD naïve psoriatic arthritis patients: results of a phase 3 randomized controlled trial (PALACE 4). ACR meeting, San Diego, 2013. Abstract L4.

39. Wells AF, Edwards CJ, Kivitz AJ et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford), 2018 Apr 4. doi: 10.1093/rheumatology/key032.

40. Mease PJ, Kavanaugh A, Gladman DD et al. Long-term safety and tolerability of apremilast, an oral phospho diesterase 4 inhibitor, in patients with psoriatic arthritis: Pooled safety analysis of three Phase 3, randomized, controlled trials. Arthritis Rheum, 2013, 65(10 Suppl.): S131-S132.

41. Nash P, Ohson K, Walsh J et al. Early and sustained effi cacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase

42. IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis, 2018 May, 77(5): 690-698. doi: 10.1136/ annrheumdis-2017-211568.

43. Celgene International Sarl, Apremilast achieves statistical signifi cance for the primary endpoint of the fi rst phase III study (PALACE-1) in patients with psoriatic arthritis [press release], Available at: http: // ir.celgene.com/phoenix.zhtml?c = 111960&p = irolnewsArticle&ID = 1714113&highlight = (Accessed August 6, 2013).

44. Goldenberg MM. Pharmaceutical Approval Update. P T, 2014 Jun, 39(6): 415-416, 423.

45. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update Ann Rheum Dis, 2015, 0: 1-12. doi: 10.1136/ annrheumdis-2015-208337.


Просмотров: 217


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)